- Sputnik International
Asia
Find top stories and features from Asia and the Pacific region. Keep updated on major political stories and analyses from Asia and the Pacific. All you want to know about China, Japan, North and South Korea, India and Pakistan, Southeast Asia and Oceania.

Japan Postpones Completion of Avigan's Clinical Trials Due to Insufficient Data - Reports

© REUTERS / Issei KatoTablets of Avigan at Fujifilm's headquarters in Tokyo
Tablets of Avigan at Fujifilm's headquarters in Tokyo - Sputnik International
Subscribe
TOKYO (Sputnik) - Clinical trials of Avigan, a Japanese anti-flu drug which has proven to be effective for treating COVID-19 patients, will not be completed on time due to lack of data as a result of falling coronavirus infection rate, Japanese media reported on Monday, citing sources in the Fujifilm Holdings Corporation pharmaceutical company.

Avigan was developed by the Fujifilm Toyama Chemical pharmaceutical company six years ago, but due to side effects on the fetus, it was excluded from use by pregnant women and included in a list of drugs to be used in exceptional circumstances with a special order from the government when no available alternatives work.

In March, Japan began conducting clinical trials on 80 coronavirus patients with mild or no coronavirus symptoms. At the moment, Japan has a supply of Avigan, sufficient to treat two million people.

Initially, the pharmaceutical company planned to complete the tests by the end of May but then extended the test period until the end of June. Yet, the company lacked 96 patients due to the drop in the number of new infections, according to the Kyodo news outlet.

As of 8 June, Japan has registered 17,174 COVID-19 cases, the World Health Organization dashboard shows. A total of 916 people have died. Over 15,000 patients have recovered.

Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала